Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: A systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 1, 2005, Pages 2-19

  Fletcher, Olivia ^a   Gibson, Lorna ^a   Johnson, Nichola ^a   Altmann, Dan R ^a   Holly, Jeffrey M P ^b   Ashworth, Alan ^a   Peto, Julian ^a   Silva, Isabel Dos Santos ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

3' UNTRANSLATED REGION; ALLELE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER RISK; ETHNOLOGY; GENE EXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 12844281089     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Wood TL, Yee D. Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:1-5.
2. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8:197-209.
3. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.
4. Maile LA, Xu S, Cwyfan-Hughes SC, Fernihough JK, Pell JM, Holly JM. Active and inhibitory components of the insulin-like growth factor binding protein-3 protease system in adult serum, interstitial, and synovial fluid. Endocrinology 1998;139:4772-81.
5. Hadsell DL, Bonnette SG. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 2000;5:19-30.
6. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 2000;19:889-98.
7. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 1995;72:1189-93.
8. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65:311-20.
9. Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993;29A:492-7.
10. Bruning PF, Van Doorn J, Bonfrer JM, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266-70.
11. Favoni RE, de Cupis A, Perrotta A, et al. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol 1995;121:674-82.
12. Kao PC, Matheny AP Jr, Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994; 78:310-2.
13. Verhaeghe J, Loos R, Vlietinck R, Herck EV, van Bree R, Schutter AM, C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in cord serum of twins: genetic versus environmental regulation. Am J Obstet Gynecol 1996;175:1180-8.
14. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5.
15. Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996;81:1791-7.
16. Jahanfar S, Eden JA, Warren P, Seppala M, Nguyen TV. A twin study of polycystic ovary syndrome. Fertil Steril 1995;63:478-86.
17. Sharp S, Sterne J. Sbe 16: Meta-analysis. Stata Tech Bull 1997;38:9-14.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
19. Del Giudice ME. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-20.
20. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27:294-9.
21. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol 1998;5:194-201.
22. Holdaway IM, Mason BH, Lethaby AE, et al. Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aust N Z J Surg 1999;69:495-500.
23. Kaulsay KK, Ng EH, Ji CY, Ho GH, Aw TC, Lee KO. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol 1999;140:164-8.
24. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999;57:330-40.
25. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
26. Jernström H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Women's Health Gend Based Med 1999;8:1265-72.
27. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6.
28. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78:744-52.
29. Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:705-12.
30. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1566-73.
31. Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11:1361-8.
32. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 2000;11:383-8.
33. Hirose K, Toyama T, Iwata H, Takezaki T, Hamajima N, Tajima K. Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev 2003;4:239-46.
34. Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-16.
35. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
36. Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullen KJ. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 2000;24:199-206.
37. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, et al. Circulating levels of insulin-like growth factor I, its binding proteins-1, -2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003;106:90-5.
38. Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001;91:736-9.
39. Crown AL, Cottle K, Lightman SL, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 2002;56:723-33.
40. Platz EA, Pollak MN, Rimm EB, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-10.
41. Hopkins KD, Lehmann ED, Jones RL, et al. Ethnicity affects IGFBP-3 and IGF-II in normal healthy young adult subjects. Clin Endocrinol (Oxf) 1996; 45:327-31.
42. Gunnell D, Oliver SE, Peters TJ, et al. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003;88:1682-6.
43. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852-61.
44. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
45. Ben-Shlomo Y, Holly J, McCarthy A, et al. An investigation of fetal, postnatal and childhood growth with insulin-like growth factor I and binding protein 3 in adulthood. Clin Endocrinol (Oxf) 2003;59:366-73.
46. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev 2002;11:758-66.
47. Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:862-7.
48. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997;145:970-6.
49. Voskuil DW, Bueno de Mesquita HB, Kaaks R, Riboli E, et al. Determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1-3 in premenopausal women: physical activity and anthropometry (Netherlands). Cancer Causes Control 2001;12:951-8.
50. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.
51. Westwood M, Gibson JM, Pennells LA, White A. Modification of plasma insulin-like growth factors and binding proteins during oral contraceptive use and the normal menstrual cycle. Am J Obstet Gynecol 1999;180:530-6.
52. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003;13:113-70.
53. Conover CA, Clarkson JT, Bale LK. Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Endocrinology 1996;137:2286-92.
54. Rotwein P, Yokoyama S, Didier DK, Chirgwin JM. Genetic analysis of the hypervariable region flanking the human insulin gene. Am J Hum Genet 1986;39:291-9.
55. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
56. Jernström H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001;72:144-54.
57. Kato I, Eastham J, Li B, Smith M, Yu H. Genotype-phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 2003;18:203-9.
58. Jernström H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
59. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.
60. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW. A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 2003;148:171-5.
61. Missmer SA, Haiman CA, Hunter DJ, et al. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 2002;100:332-6.
62. Allen NE, Davey GK, Key TJ, Zhang S, Narod SA. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 2002;11:319-20.
63. Kim JG, Roh KR, Lee JY. The relationship among serum insulin-like growth factor-I, insulin-like growth factor-I gene polymorphism, and bone mineral density in postmenopausal women in Korea. Am J Obstet Gynecol 2002;186:345-50.
64. Frayling TM, Hattersley AT, McCarthy A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 2002;51:2313-6.
65. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN, Hunter DJ. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2002;11:1509-10.
66. DeLellis K, Ingles S, Kolonel L, et al. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 2003;88:277-82.
67. Xu J, Turner A, Little J, Bleecker ER, Meyers DA. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet 2002;111:573-4.
68. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-9.
69. Rasmussen SK, Lautier C, Hansen L, et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85: 1606-10.
70. Arends N, Johnston L, Hokken-Koelega A, et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 2002;87:2720.
71. Holthuizen PE, Steenbergh PH, Sussenbach JS. Regulation of IGF gene expression. In Rosenfeld RG, Roberts CT Jr, editors. The IGF system: molecular biology, physiology, and clinical applications. Vol. 17. Totowa (NJ): Humana Press; 1999. p. 37-61.
72. Gaunt TR, Cooper JA, Miller GJ, Day IN, O'Dell SD. Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males. Hum Mol Genet 2001;10:1491-501.
73. O'Dell SD, Miller GJ, Cooper JA, et al. ApI polymorphism in insulin-like growth factor II (IGF2) gene and weight in middle-aged males. Int J Obes Relat Metab Disord 1997;21:822-5.
74. Phillips LS, Pao CI, Villafuerte BC. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucleic Acid Res Mol Biol 1998;60:195-265.
75. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80.
76. Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat 2001;70: 117-22.
77. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics 1997;53:1253-61.
78. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform 2002;3:146-53.
79. Figer A, Karasik YP, Baruch KG, et al. Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women. Isr Med Assoc J 2002;4:759-62.
80. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4.
81. Yu H, Shu XO, Li BD, et al. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:1067-73.
82. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5: 107-15.
83. Giani C, Cullen KJ, Campani D, Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 1996;41:43-50.
84. Paik S. Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992;22:31-8.
85. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat Genet 2003;33 Suppl:228-37.
86. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993;329:517-23.
87. Firgaira FA, Seshadri R, McEvoy CR, et al. HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J Natl Cancer Inst 1999;91:2107-11.
88. Tamimi RM, Hankinson SE, Ding S, et al. The HRAS1 variable number of tandem repeats and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1528-30.
89. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-80.
90. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
91. Offit K, Pierce H, Kirchhoff T, et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003;4:1.